{"id":58301,"date":"2026-02-27T19:28:28","date_gmt":"2026-02-27T11:28:28","guid":{"rendered":"https:\/\/flcube.com\/?p=58301"},"modified":"2026-02-27T19:28:30","modified_gmt":"2026-02-27T11:28:30","slug":"jumpcan-pharma-secures-china-rights-to-thedermas-tap-1503-first-ahr-modulator-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58301","title":{"rendered":"Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 \u2013 First AhR Modulator for Atopic Dermatitis"},"content":{"rendered":"\n

Jumpcan Pharmaceutical (SHA:\u202f600566<\/a>)<\/strong> announced a cooperation agreement<\/strong> with Shanghai\u2011based Thederma<\/strong>, securing exclusive commercialization rights<\/strong> in Mainland China<\/strong> (excluding Hong Kong, Macau, and Taiwan) for TAP-1503 (benvitimod 1% cream)<\/strong>. The product is the world’s first approved aryl hydrocarbon receptor (AhR) modulator<\/strong> for atopic dermatitis (AD)<\/strong>, approved by NMPA in November\u202f2024<\/strong>, and fills a critical gap in non\u2011hormonal topical treatment<\/strong> for pediatric patients.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Thederma (Shanghai\u2011based)<\/td><\/tr>
Licensee<\/strong><\/td>Jumpcan Pharmaceutical (SHA:\u202f600566)<\/td><\/tr>
Product<\/strong><\/td>TAP-1503 (benvitimod 1% cream)<\/td><\/tr>
Territory<\/strong><\/td>Mainland China (exclusive)<\/td><\/tr>
Rights Granted<\/strong><\/td>Commercialization<\/td><\/tr>
Excluded Territories<\/strong><\/td>Hong Kong SAR, Macau SAR, Taiwan region<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 TAP-1503<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>Aryl hydrocarbon receptor (AhR) modulator<\/td><\/tr>
Innovation Status<\/strong><\/td>World’s first approved AhR modulator<\/strong> for AD<\/td><\/tr>
Approval Date<\/strong><\/td>November\u202f2024 (NMPA)<\/td><\/tr>
Indication<\/strong><\/td>Atopic dermatitis (AD)<\/td><\/tr>
Patient Population<\/strong><\/td>Children aged \u2265\u202f2 years + adults<\/td><\/tr>
Formulation<\/strong><\/td>1% cream (topical)<\/td><\/tr>
Mechanism<\/strong><\/td>Dual action: suppresses inflammatory factors + repairs skin barrier<\/td><\/tr>
Differentiation<\/strong><\/td>Non\u2011hormonal<\/strong> \u2013 addresses safety concerns of corticosteroids in pediatric use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Value Proposition<\/h2>\n\n\n\n
Traditional AD Treatments<\/th>TAP-1503 Advantage<\/th><\/tr><\/thead>
Topical corticosteroids<\/td>Hormone\u2011free; no skin atrophy or systemic absorption risks<\/td><\/tr>
Calcineurin inhibitors<\/td>Superior efficacy; barrier repair function<\/td><\/tr>
General moisturizers<\/td>Active anti\u2011inflammatory + barrier restoration<\/td><\/tr>
Pediatric Limitations<\/strong><\/td>First safe, effective non\u2011hormonal option for children \u2265\u202f2 years<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n